Inflammation, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 27, 2024
Language: Английский
International Forum of Allergy & Rhinology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 8, 2025
ABSTRACT Introduction Tissue eosinophil counts (TEC) might serve as a biomarker linking chronic rhinosinusitis (CRS) and the presence of adult‐onset asthma. This study aimed to determine if TEC in sinus mucosa/polyps CRS patients is an independent indicator asthma identify its optimal cut‐off point. Methods cross‐sectional was conducted on primary scheduled for surgery. All were assessed by pulmonologist diagnosis. Tissues collected during surgery evaluated TEC. Logistic regression receiver operating characteristic analysis used significant factors points associated with Results A total 103 included. Ten (9.7%) had underlying asthma, while 13 (12.6%) first diagnosed pulmonologist. ≥40 cells per high‐powered field (HPF) exhibited correlation (area under curve = 0.71, p < 0.001). The sensitivity this point 0.70 (95% confidence interval [CI] 0.47–0.87), specificity 0.66 CI 0.55–0.76). Positive predictive value negative 0.37 0.88, respectively. significantly adjusted odds ratio 3.13 1.05–9.35, 0.04), controlling polyps, allergic rhinitis, computerized tomography (CT) score. Conclusion can help threshold cells/HPF. allergy, CT
Language: Английский
Citations
2
Respirology, Journal Year: 2024, Volume and Issue: 29(10), P. 869 - 879
Published: June 7, 2024
Abstract Background and Objective Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy safety, thereby being potentially able to elicit clinical remission on‐treatment severe eosinophilic asthma (SEA). The main goal this multicentre observational study was verify the effectiveness in inducing sustained SEA patients with or without comorbid chronic rhinosinusitis nasal polyps (CRSwNP). Methods Throughout 2 years treatment benralizumab, four‐component evaluation performed, including assessment exacerbations, use oral corticosteroids (OCSs), symptom control lung function. Results present recruited 164 suffering from SEA. After 24 months add‐on biological therapy 69 (42.1%) achieved important target (exacerbation rate = 0, OCS dose pre‐bronchodilator FEV 1 ≥80% pred., ACT score ≥ 20). During same period, persistent improvement CRSwNP (SNOT‐22 < 30, NP recurrence 0) observed 33 (40.2%) out 82 subjects concomitant NP. latter comorbidity post‐bronchodilator reversibility airflow limitation were two independent predictors (OR 2.32, p 0.05 OR 5.59, 0.01, respectively). Conclusion Taken together, results real‐life investigation indicate can induce SEA, especially those reversible limitation. image
Language: Английский
Citations
14
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 730 - 730
Published: Jan. 5, 2024
Chronic rhinosinusitis (CRS) has recently undergone a significant paradigm shift, moving from phenotypical classification towards an "endotype-based" definition that places more emphasis on clinical and therapeutic aspects. Similar to other airway diseases, like asthma, most cases of CRS in developed countries exhibit dysregulated type-2 immune response related cytokines. Consequently, the traditional distinction between upper lower airways been replaced by "united airway" perspective. Additionally, disorders extend beyond respiratory boundaries, encompassing conditions airways, such as atopic dermatitis. This necessitates multidisciplinary approach. Moreover, consideration possible systemic implications is crucial, particularly relation sleep-related breathing diseases Obstructive Sleep Apnoea Syndrome (OSAS) alteration inflammatory mediators nitric oxide. The trends epidemiological, economic, social burden are progressively increasing worldwide, indicating syndemic characteristics. In light these insights, this narrative review aims present latest evidence disorders, with specific focus while promoting comprehensive perspective airways". It also introduces novel concept: viewing multiorgan, systemic, disease.
Language: Английский
Citations
9
Current Allergy and Asthma Reports, Journal Year: 2023, Volume and Issue: 24(1), P. 11 - 23
Published: Dec. 12, 2023
The development of biological therapies for type 2 inflammatory diseases raises the possibility addressing remission in those dis-immune conditions. No consensus exists a definition chronic rhinosinusitis with nasal polyps (CRSwNP). This review aims to critically evaluate published data provide basis defining CRSwNP.
Language: Английский
Citations
13
Current Opinion in Allergy and Clinical Immunology, Journal Year: 2024, Volume and Issue: 24(4), P. 230 - 236
Published: April 30, 2024
Purpose of review The aim this study was Describe the latest evidence related to concept clinical remission in patients with severe asthma, focusing on lights and shadows concept. Recent findings idea asthma brings about a significant shift way is treated managed. Although there has yet be unanimous agreement among various scientific societies precise definition, can extremely useful advancing treatment disease. Summary Asthma common respiratory condition that affects more than 300 million people globally. It variable symptoms severity levels, 10% experiencing asthma. While have been advancements treatment, poses challenges. approaches focused achieving remission, which goes beyond symptom control address underlying inflammation biological processes. Clinical criteria include absence symptoms, reduced medication usage, normalized inflammatory markers. Various biologic therapies show promise, some remission. However, remission's definition varies globally, hindering standardization valid comparison. Standardizing refining predictive factors are crucial for effective management. Overall, offers hope improved long-term outcomes patients.
Language: Английский
Citations
5
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(3), P. 957 - 957
Published: Feb. 2, 2025
Background: Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are respiratory conditions that frequently coexist. However, an integrated assessment tool for both is currently lacking. This study aimed to develop preliminarily evaluate a composite score capable of simultaneously assessing asthma CRSwNP in comorbid patients. Methods: An expert panel comprising three pulmonologists, one allergist/clinical immunologist, four ear, nose throat (ENT) specialists developed capture severity. The (D’Amato-De Corso score, or DAMADECO score) incorporates eight parameters, specific CRSwNP, assign individual scores each condition. A then calculated reflect the overall disease burden (ranging from −8: poor control +8: optimal control). retrospective pilot was conducted tool. Results: applied 21 mean partial were −1.57 −1.67, respectively, total −3.24. 13 out patients had uncontrolled domains diseases, while fewer only (1/21) (6/21). also allows researchers track progression monitor treatment effectiveness. Conclusions: preliminary results suggest promising addressing unmet need approach diseases. Further validation studies needed validate larger patient populations.
Language: Английский
Citations
0
Respiratory Medicine, Journal Year: 2025, Volume and Issue: 240, P. 108024 - 108024
Published: March 3, 2025
Language: Английский
Citations
0
Immunologic Research, Journal Year: 2025, Volume and Issue: 73(1)
Published: March 11, 2025
The epithelial barrier in different organs is the first line of defense against environmental insults and allergens, with type 2 immunity serving as a protective function. Genetic factors, biological chemical from surrounding environment altered regulate homeostasis through disruption tight junction proteins or dilated intercellular spaces. Recent studies suggest that dysfunction contributes to pathologic alteration diseases immune dysregulation including (but not limited to) atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis nasal polyps, eosinophilic esophagitis. In this review, we summarized current understanding its interaction inflammation across organs, discussed role pathogenesis inflammation. addition, recent progresses emerging restorative therapies are reviewed.
Language: Английский
Citations
0
Asia Pacific Allergy, Journal Year: 2025, Volume and Issue: unknown
Published: March 20, 2025
Background: Among the different endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic CRSwNP (ECRSwNP) exhibits more severe symptoms and a higher rate recurrence compared noneosinophilic (non-ECRSwNP), as well distinct metabolic alterations. Hence, early identification alterations in is crucial for prediction selection personalized treatment patients CRSwNP, especially ECRSwNP. However, clinical practice faces deficiency readily accessible expedited predictive diagnostics changes. Objective: This study aimed to assess capacity 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) concentrations secretions classify predict CRSwNP. Methods: Levels 15(S)-HETE were measured via enzyme-linked immunosorbent assay (ELISA) 57 ECRSwNP 49 non-ECRSwNP. The expression distribution ALOX15 assessed by immunohistochemical staining. In addition, multivariate logistic regression analysis was conducted identify factors polyp recurrence. optimal cutoff value determined point on receiver operating characteristic (ROC) curve maximum Youden Index. Results: concentration significantly group (median [interquartile range (IQR)]: 294.34 ng/mL [83.23–701.34 ng/mL]) than non-ECRSwNP [IQR]: 100.19 [25.53–207.25 ( P < 0.0001). Furthermore, it positively correlated eosinophil counts percentage tissue r = 0.620, 0.001 0.487, 0.001, respectively). Multivariate showed that risk factor (odds ratio 1.004, 95% confidence interval 1.001–1.008, 0.022), ROC (area under 0.890, 0.001). Conclusion: secretions, ELISA, can serve reliable alternative indicator identifying predicting
Language: Английский
Citations
0
Frontiers in Allergy, Journal Year: 2025, Volume and Issue: 6
Published: March 20, 2025
Introduction Severe eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis nasal polyps (CRSwNP), worsening symptoms. Earlier studies have shown that benralizumab improves outcomes greater efficacy if patients present CRSwNP. Methods This post hoc analysis of the ANANKE study (NCT04272463) reports data on long-term effectiveness between SEA and without CRSwNP ( N = 86 75, respectively) treated for up to 96 weeks. Results Before initiation, displayed longer duration, oral corticosteroid (OCS) use blood eosinophil count. After weeks treatment, annual exacerbation rate (AER) decreased in both groups, achieving considerable reductions than No-CRSwNP (severe AER dropped by 100% 95.6%, respectively). While lung function improvement was comparable at week 96, showed a faster response benralizumab, rise forced expiratory volume 1 s (FEV ) 16 maintained throughout study. Median OCS daily dose 0.0 mg groups weeks, but OCS-sparing effect (median 2.5 respectively, 48 weeks). Although control test (ACT) median scores were comparable, proportions well-controlled (ACT ≥ 20) all time points. Discussion These findings show CRSwNP, highlighting its superior faster-acting benefits presence
Language: Английский
Citations
0